Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Conley

Showing results (551-560 of 563) with videos related to

Pageof 57
Sort By:
ESMO Open|June 25, 2025
Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcomaR S Traweek, M Zoghbi, R Lazcano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial UpdateAlice P Chen, Christina L Rosenberger, Nancy Moore, et al.
Journal of Neurotrauma|December 7, 2018
Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh VisionPatrick M Kochanek, Travis C Jackson, Ruchira M Jha, et al.
Frontiers in Oncology|October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcomaRossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
The New England Journal of Medicine|September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part SarcomaAlice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
Journal of the National Cancer Institute|September 9, 2024
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairmentMichelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, et al.
Nature Methods|September 24, 2005
The External RNA Controls Consortium: a progress reportShawn C Baker, Steven R Bauer, Richard P Beyer, et al.
International Journal of Epidemiology|January 19, 2012
Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtypeReecha Sofat, Juan P Casas, Andrew R Webster, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Pageof 57

Showing results (551-560 of 563) with videos related to

Sort By:
Pageof 57
ESMO Open|June 25, 2025
Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcomaR S Traweek, M Zoghbi, R Lazcano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial UpdateAlice P Chen, Christina L Rosenberger, Nancy Moore, et al.
Journal of Neurotrauma|December 7, 2018
Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh VisionPatrick M Kochanek, Travis C Jackson, Ruchira M Jha, et al.
Frontiers in Oncology|October 31, 2022
The immune landscape of undifferentiated pleomorphic sarcomaRossana Lazcano, Carmelia M Barreto, Ruth Salazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
The New England Journal of Medicine|September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part SarcomaAlice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
Journal of the National Cancer Institute|September 9, 2024
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairmentMichelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, et al.
Nature Methods|September 24, 2005
The External RNA Controls Consortium: a progress reportShawn C Baker, Steven R Bauer, Richard P Beyer, et al.
International Journal of Epidemiology|January 19, 2012
Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtypeReecha Sofat, Juan P Casas, Andrew R Webster, et al.
Nature Cancer|February 13, 2024
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcomaChristina L Roland, Elise F Nassif Haddad, Emily Z Keung, et al.
Pageof 57